Biology Reference
In-Depth Information
[46] Hsieh MM, Kang EM, Fitzhugh CD, Link MB, Bolan CD, Kurlander R, et al. Alloge-
neic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med
2009;361(24):2309-17.
[47] Kasamon YL, Luznik L, Leffell MS, Kowalski J, Tsai HL, Bolanos-Meade J, et al. Non-
myeloablative HLA-haploidentical bone marrow transplantation with high-dose
posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood
Marrow Transplant 2010;16(4):482-9.
[48] Luznik L, Jones RJ, Fuchs EJ. High-dose cyclophosphamide for graft-versus-host disease
prevention. Curr Opin Hematol 2010;17(6):493-9.
[49] Luznik L, Bolanos-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, et al. High-dose
cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host dis-
ease. Blood 2010;115(16):3224-30.
[50] Pulsipher MA, Bader P, Klingebiel T, Cooper LJ. Allogeneic transplantation for pediat-
ric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal
residual disease/chimerism monitoring and novel chemotherapeutic, molecular,
and immune approaches aimed at preventing relapse. Biol Blood Marrow Transplant
2009;15(1 Suppl):62-71.
[51] Coustan-Smith E, Ribeiro RC, Rubnitz JE, Razzouk BI, Pui CH, Pounds S, et al. Clinical
significance of residual disease during treatment in childhood acute myeloid leukaemia.
Br J Haematol 2003;123(2):243-52.
[52] Maurillo L, Buccisano F, Del Principe MI, Del Poeta G, Spagnoli A, Panetta P, et al.
Toward optimization of postremission therapy for residual disease-positive patients with
acute myeloid leukemia. J Clin Oncol 2008;26(30):4944-51.
[53] Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, et al. Minimal residual
disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02
multicentre trial. Lancet Oncol 2010;11(6):543-52.
[54] Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, et al. Impact of pretrans-
plantation minimal residual disease, as detected by multiparametric flow cytometry,
on outcome of myeloablative hematopoietic cell transplantation for acute myeloid
leukemia. J Clin Oncol 2011;29(9):1190-7.
[55] Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, et al. Reinduction
platform for children with first marrow relapse of acute lymphoblastic leukemia: a Chil-
dren's Oncology Group Study [corrected]. J Clin Oncol 2008;26(24):3971-8.
[56] Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P, et al. Increasing
mixed chimerism is an important prognostic factor for unfavorable outcome in children
with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible
role for pre-emptive immunotherapy? J Clin Oncol 2004;22(9):1696-705.
[57] Sockel K, Ehninger G, Hofbauer LC, Platzbecker U. Optimizing management of
myelodysplastic syndromes post-allogeneic transplantation. Expert Rev Hematol
2011;4(6):669-80.
[58] Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, Leil TA, et al. Chemoim-
munotherapy reinduction with epratuzumab in children with acute lymphoblastic
leukemia in marrow relapse: a Children's Oncology Group pilot study. J Clin Oncol
2008;26(22):3756-62.
[59] Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted
therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory
minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in
high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29(18):2493-8.
[60] Magenau J, Tobai H, Pawarode A, Braun T, Peres E, Reddy P, et al. Clofarabine and busul-
fan conditioning facilitates engraftment and provides significant antitumor activity in
nonremission hematologic malignancies. Blood 2011;118(15):4258-64.
[61] Satwani P, Bhatia M, Garvin JH Jr, George D, Dela Cruz F, Le Gall F, Jin Z, et al. A phase I
study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophos-
phamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk
CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC)
regimen. Biol Blood Marrow Transplant 2012;18(2):324-9.
[62] Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness
of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Sci-
ence 2002;295(5562):2097-100.
[63] Brunstein CG, Wagner JE, Weisdorf DJ, Cooley S, Noreen H, Barker JN, et al. Negative
effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on
transplantation conditioning intensity. Blood 2009;113(22):5628-34.
[64] Willemze R, Rodrigues CA, Labopin M, Sanz G, Michel G, Socie G, et al. KIR-ligand in-
compatibility in the graft-versus-host direction improves outcomes after umbilical cord
blood transplantation for acute leukemia. Leukemia 2009;23(3):492-500.
507
Search WWH ::
Custom Search